title: Molecular targeted therapies for renal cell carcinoma.
abstract: New advances in technology to directly target specific molecular events in the proliferation of cancer have led to promising results in renal cell carcinoma. Response rates in excess of 70% and complete responses in advanced (metastatic) renal cell carcinoma have caused a change in the paradigm of treatment from immunotherapy. Toxicities are significant, but manageable and pushing the toxicity to tolerability may increase the response rate.
authors.affiliation: Urologic Specialists of Virginia, Richmond, VA 23225, USA.
authors.forename: Sam D
authors.initials: SD
authors.lastname: Graham
authors.forename: Mary Elizabeth
authors.initials: ME
authors.lastname: Warden
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Lou
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007680:Kidney Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents